Allergan Announces Completion of UBR-MD-04 & 3110-105-002 Study for Treatment of Migrane
Shots:
- The two pivotal study conducted for assessing ubrogepant (50/100) vs usual care & ubrogepant (100) vs PBO for 1year & 8 wks. respectively to treat migrane in adults- evaluating its safety- tolerability & hepatic safety
- UBR-MD-04 (N=1-254) & 3110-105-002(N=516) study results: 21-454 migraine attacks were treated with 31-968 doses of ubrogepant with mean number 25.5 (50 mg) and 27.2 (100 mg) @52wks.; no signal of drug-induced liver injury or a hepatic safety concern was observed
- Allegan plans to file NDA submission with efficacy and safety results from ACHIEVE I & II (UBR-MD-01 & UBR-MD-02)- UBR-MD-04 & 3110-105-002 in H1’19
Ref: Novartis | Image: Endpts
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com